FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325635634> ?p ?o ?g. }

• W2325635634 endingPage "737" @default.
• W2325635634 startingPage "730" @default.
• W2325635634 abstract "In Brief BACKGROUND: Obesity is a significant risk factor for surgical site infections (SSIs), for poorly understood reasons. SSIs are a major cause of morbidity, prolonged hospitalization, and increased health care cost. Drug disposition in general is frequently altered in the obese. Preoperative antibiotic administration, achieving adequate tissue concentrations at the time of incision, is an essential strategy to prevent SSIs. Nonetheless, there is little information regarding antibiotic concentrations in obese surgical patients. This investigation tested the hypothesis that the prophylactic antibiotic cefoxitin may have delayed and/or diminished tissue penetration in the obese. METHODS: Plasma and tissue concentrations of cefoxitin were determined in obese patients undergoing abdominal and pelvic surgery (body mass index 43 ± 10 kg/m2, n = 14, 2 g cefoxitin) and in normal-weight patients and healthy volunteers (body mass index 20 ± 2 kg/m2, n = 13, 1 g cefoxitin). Tissue concentrations were measured using a microdialysis probe in the subcutaneous layer of the abdomen, and in adipose tissue excised at the time of incision and wound closure. RESULTS: Plasma concentrations and area under the concentration-time curve (AUC) were approximately 2-fold higher in the obese patients because of the 2-fold-higher dose. Dose-normalized concentrations were higher, although AUCs were not significantly different. Measured and dose-normalized subcutaneous cefoxitin concentrations and AUCs in the obese patients were significantly lower than in the normal-weight subjects. There was an inverse relationship between cefoxitin tissue penetration (AUCtissue/AUCplasma ratio) and body mass index. Tissue penetration was substantially lower in the obese patients (0.08 ± 0.07 vs 0.37 ± 0.26, P < 0.05). Adipose tissue cefoxitin concentrations in obese patients were only 7.8 ± 7.3 and 2.7 ± 1.4 μg/g, respectively, at incision and closure, below the minimum inhibitory concentration of 8 and 16 μg/mL, respectively, for aerobic and anaerobic microorganisms. CONCLUSION: Obese surgical patients have impaired tissue penetration of the prophylactic antibiotic cefoxitin, and inadequate tissue concentrations despite increased clinical dose (2 g). Inadequate tissue antibiotic concentrations may be a factor in the increased risk of SSIs in obese surgical patients. Additional studies are needed to define doses achieving adequate tissue concentrations. Published ahead of print June 3, 2011" @default.
• W2325635634 created "2016-06-24" @default.
• W2325635634 creator A5006183595 @default.
• W2325635634 creator A5012844446 @default.
• W2325635634 creator A5028621657 @default.
• W2325635634 creator A5056186200 @default.
• W2325635634 creator A5062197867 @default.
• W2325635634 creator A5064549304 @default.
• W2325635634 date "2011-10-01" @default.
• W2325635634 modified "2023-10-11" @default.
• W2325635634 title "Pharmacokinetics and Tissue Penetration of Cefoxitin in Obesity" @default.
• W2325635634 cites W1483408623 @default.
• W2325635634 cites W1970669539 @default.
• W2325635634 cites W1987263914 @default.
• W2325635634 cites W1989525615 @default.
• W2325635634 cites W1991973566 @default.
• W2325635634 cites W1998520760 @default.
• W2325635634 cites W2002433934 @default.
• W2325635634 cites W2004550026 @default.
• W2325635634 cites W2005033162 @default.
• W2325635634 cites W2005891936 @default.
• W2325635634 cites W2009458519 @default.
• W2325635634 cites W2021689494 @default.
• W2325635634 cites W2026872707 @default.
• W2325635634 cites W2031333983 @default.
• W2325635634 cites W2035828766 @default.
• W2325635634 cites W2046859247 @default.
• W2325635634 cites W2057823893 @default.
• W2325635634 cites W2058104808 @default.
• W2325635634 cites W2058424608 @default.
• W2325635634 cites W2070225078 @default.
• W2325635634 cites W2070622079 @default.
• W2325635634 cites W2079691262 @default.
• W2325635634 cites W2086524386 @default.
• W2325635634 cites W2092441666 @default.
• W2325635634 cites W2092672763 @default.
• W2325635634 cites W2100143826 @default.
• W2325635634 cites W2106891451 @default.
• W2325635634 cites W2107564745 @default.
• W2325635634 cites W2117679891 @default.
• W2325635634 cites W2119051310 @default.
• W2325635634 cites W2130945648 @default.
• W2325635634 cites W2135705057 @default.
• W2325635634 cites W2135939164 @default.
• W2325635634 cites W2158407329 @default.
• W2325635634 cites W2165696195 @default.
• W2325635634 cites W2168148812 @default.
• W2325635634 cites W2170719669 @default.
• W2325635634 cites W4229738864 @default.
• W2325635634 cites W82676691 @default.
• W2325635634 doi "https://doi.org/10.1213/ane.0b013e31821fff74" @default.
• W2325635634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21642605" @default.
• W2325635634 hasPublicationYear "2011" @default.
• W2325635634 type Work @default.
• W2325635634 sameAs 2325635634 @default.
• W2325635634 citedByCount "97" @default.
• W2325635634 countsByYear W23256356342012 @default.
• W2325635634 countsByYear W23256356342013 @default.
• W2325635634 countsByYear W23256356342014 @default.
• W2325635634 countsByYear W23256356342015 @default.
• W2325635634 countsByYear W23256356342016 @default.
• W2325635634 countsByYear W23256356342017 @default.
• W2325635634 countsByYear W23256356342018 @default.
• W2325635634 countsByYear W23256356342019 @default.
• W2325635634 countsByYear W23256356342020 @default.
• W2325635634 countsByYear W23256356342021 @default.
• W2325635634 countsByYear W23256356342022 @default.
• W2325635634 countsByYear W23256356342023 @default.
• W2325635634 crossrefType "journal-article" @default.
• W2325635634 hasAuthorship W2325635634A5006183595 @default.
• W2325635634 hasAuthorship W2325635634A5012844446 @default.
• W2325635634 hasAuthorship W2325635634A5028621657 @default.
• W2325635634 hasAuthorship W2325635634A5056186200 @default.
• W2325635634 hasAuthorship W2325635634A5062197867 @default.
• W2325635634 hasAuthorship W2325635634A5064549304 @default.
• W2325635634 hasBestOaLocation W23256356341 @default.
• W2325635634 hasConcept C112705442 @default.
• W2325635634 hasConcept C126322002 @default.
• W2325635634 hasConcept C126894567 @default.
• W2325635634 hasConcept C141071460 @default.
• W2325635634 hasConcept C171089720 @default.
• W2325635634 hasConcept C2776124114 @default.
• W2325635634 hasConcept C2777300098 @default.
• W2325635634 hasConcept C2778353156 @default.
• W2325635634 hasConcept C2779489039 @default.
• W2325635634 hasConcept C2780221984 @default.
• W2325635634 hasConcept C42219234 @default.
• W2325635634 hasConcept C50156730 @default.
• W2325635634 hasConcept C501593827 @default.
• W2325635634 hasConcept C511355011 @default.
• W2325635634 hasConcept C523546767 @default.
• W2325635634 hasConcept C529278444 @default.
• W2325635634 hasConcept C54355233 @default.
• W2325635634 hasConcept C71924100 @default.
• W2325635634 hasConcept C86803240 @default.
• W2325635634 hasConcept C89423630 @default.
• W2325635634 hasConcept C90924648 @default.
• W2325635634 hasConceptScore W2325635634C112705442 @default.

• next